Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Sep 3.
Published in final edited form as: Cell Rep. 2026 Jun 17;45(7):117627. doi: 10.1016/j.celrep.2026.117627

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition

Andrew M Waters, Tala O Khatib, Bjoern Papke, Craig M Goodwin, G Aaron Hobbs, J Nathaniel Diehl, Runying Yang, A Cole Edwards, Katherine H Walsh, Rita Sulahian, James M McFarland, Kevin S Kapner, Thomas SK Gilbert, Clint A Stalnecker, Sehrish Javaid, Anna Barkovskaya, Kajal R Grover, Priya S Hibshman, Devon R Blake, Antje Schaefer, Katherine M Nowak, Jennifer E Klomp, Tikvah K Hayes, Michelle Kassner, Nanyun Tang, Olga Tanaseichuk, Kaisheng Chen, Yingyao Zhou, Manpreet Kalkat, Laura E Herring, Lee M Graves, Linda Z Penn, Hongwei H Yin, Andrew J Aguirre, William C Hahn, Adrienne D Cox, Channing J Der *
PMCID: PMC13536747  NIHMSID: NIHMS2199955  PMID: 42308106

There are errors in two figures of this paper. In Figure 6C, the p130Cas, total ERK, and phospho-p130Cas immunoblots inadvertently display alternative exposures from Figure 3D. In Figure S10B, images of four KX2-391-treated ex vivo tumors were inadvertently duplicated in the ERKi-treated ex vivo tumors. Although the paper itself cannot be updated due to the amount of time that has passed since its original publication, this correction notice presents the corrected figures for the scientific record.

Figure 6.

Figure 6.

KX2-391 + ERKi combinations drive robust synergistic apoptosis (corrected)

Neither issue affected the interpretation of the data or the conclusions of the study. The authors apologize for any confusion that the errors may have caused.

Supplementary Material

1

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES